BoneAlbumin induces better bone formation
Positive results in a double-blind controlled study in the knee.
A double-blind, controlled study with OrthoSera's BoneAlbumin — the company's first marketed product — has been accepted for publication in International Orthopedics. The technology is covered by a patent, which has recently been granted by the European Patent Office and is already issued in the US.
The technology is based on the proprietary serum albumin coating of bone allografts, a fully-human bone substitute that has shown strong stem cell induction capacity. This feature is unique among cell-free bone grafts as this is the only off-the-shelf tissue product that is capable of further enhancing the innate bone inducing ability of allografts. The current study has proven with high statistical significance that BoneAlbumin implantation not only results in better remodeling on CT images but significantly reduced pain at the implantation site even 6 months after surgery. In the sports medicine field anterior cruciate ligament (ACL) replacement with patellar bone-tendon-bone (BTB) autograft is the first choice of implant by many surgeons, especially for athletes with high demands on the knee joint. Donor-site pain is the major side-effect of BTB harvesting and the current study has shown that it can be avoided by a novel, off-the-shelf bone graft implantation. This is a significant step forward in bone tissue engineering as it achieves better implantation abilities without the cost or complexity of cell-based therapies.
BoneAlbumin is already in use in the European dental market with almost 1,000 successful implantations since its introduction in late 2015 and additional clinical indications being investigated by key opinion leaders in orthopedics.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance